SARS-CoV-2 test patterns in Danish patients with inflammatory rheumatic diseases during the COVID-19 pandemic

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors wish to acknowledge the Danish Departments of Clinical Microbiology and Statens Serum Institut for carrying out laboratory analysis, registration, and release of the national SARS-CoV-2 surveillance data used in the present study. Further, the authors wish to thank all the Danish Departments of Rheumatology for reporting to the DANBIO register.

Disclosure statement

Ali Hadi Abd Alzubaidi, René Cordtz, Rasmus Westermann, Karen Buch Lauridsen, and Salome Kristensen have no conflicts of interests. Bolette Gylden Soussi has received a research grant from the Danish Rheumatism Association and has stocks in Novo Nordisk. Lene Dreyer has received research support from Janssen, UCB, and Boehringer Ingelheim for attending meetings and/or travel, has a research grant/contract with BMS outside the present work, has a leadership role with a Chair in the Scientific Committee of the Danish Rheumatism Association, and is a member of the Danish National Ethical committee 3 and the steering committee of DANBIO.

Patient and public involvement statement

It was not appropriate or possible to involve patients or the public in the design, conduct, reporting, or dissemination plans of our research.

Additional information

Funding

The study was funded by Aalborg University Hospital. The funder had no influence on the planning, design, and analyses of the study, or the interpretation of the data and results.